Jonsson Comprehensive Cancer Center
🇺🇸United States
Bortezomib in Treating Patients With Metastatic Kidney Cancer
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2020-09-01
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT00276614
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer
Phase 2
Completed
- Conditions
- AnemiaLeukemiaLymphomaLymphoproliferative DisorderMultiple Myeloma and Plasma Cell NeoplasmPrecancerous ConditionUnspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Biological: epoetin alfa
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2012-10-04
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 89
- Registration Number
- NCT00255749
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery
Phase 3
Withdrawn
- Conditions
- Cholangiocarcinoma of the Extrahepatic Bile DuctCholangiocarcinoma of the GallbladderUnresectable Extrahepatic Bile Duct CancerUnresectable Gallbladder CancerRecurrent Extrahepatic Bile Duct CancerRecurrent Gallbladder Cancer
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00253617
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
🇨🇦Axcan Pharma, Incorporated, Mont-Saint-Hilaire, Quebec, Canada
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
Phase 1
Terminated
- Conditions
- LeukemiaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT00234000
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT00182637
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Lymphoma
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00138164
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate
Phase 2
- Conditions
- Leukemia
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2011-06-07
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00112775
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria
Phase 3
Completed
- Conditions
- Leukemia
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00112983
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer
Phase 2
Terminated
- Conditions
- Breast CancerFatigue
- Interventions
- Biological: infliximabOther: Clinical AssessmentOther: Self-report questionnairesOther: Immune Assessment
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT00112749
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma
Phase 1
Completed
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- Biological: therapeutic autologous dendritic cells
- First Posted Date
- 2005-04-06
- Last Posted Date
- 2020-08-05
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT00107185
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
© Copyright 2025. All Rights Reserved by MedPath